Cereno Scientific (CRNO) Company presentation summary

Company overview and strategy

• Focuses on disease-modifying therapies for rare cardiopulmonary diseases using HDAC inhibition and epigenetic modulation, aiming to slow, halt, or reverse disease progression.

• Founded in 2012 in Sweden, with headquarters in Gothenburg and a subsidiary in Boston; listed on Nasdaq First North.

• Leadership team has deep biotech, pharma, and deal-making experience.

• Holds a market cap of $170 million as of June 2026, with over 12,000 retail shareholders.

Scientific and clinical validation

• HDAC inhibition targets core drivers: vascular remodeling, fibrosis, inflammation, and thrombosis.

• 37 research articles in 2025 validate the therapeutic potential and need for disease-modifying therapies.

• Endorsed by leading global PAH key opinion leaders and supported by major patient networks.

• Preclinical and Phase IIa data for CS1 show reversal of pathological remodeling, improved heart function, and reduced mortality risk in PAH.

Pipeline and development milestones

• CS1 (oral HDAC inhibitor) in Phase IIb for PAH, with strong safety, efficacy signals, and regulatory designations (Orphan Drug, Fast Track).

• CS014 (next-gen HDAC inhibitor) Phase IIb-ready for PH-ILD, with strong preclinical and Phase I validation.

• CS585 in preclinical evaluation for rare thrombotic disorders.

• Phase IIb global PAH trial for CS1 started June 2026, targeting 126 patients across 65 sites in 10-12 countries; topline results expected Q4 2028.

• CS014 Phase IIb PH-ILD trial submission and IND approval targeted for Q3/Q4 2026.